Clinical trial
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal…
NCT04425629 · Regeneron Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT04425629 |
|---|---|
| Title | Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 |
| Official title | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug |
| Interventions | casirivimab+imdevimab combination therapy |
| Enrollment | 10,078 |
| Start date | Jun 16, 2020 |
| Primary completion | Jan 21, 2022 |
| Completion | Jun 9, 2022 |
| First posted | Jun 11, 2020 |
| Last update posted | Dec 21, 2023 |
| Countries | Mexico, Romania, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: